Pharmaceuticals company Lupin announced Q3FY25 results Gross Profit was Rs 38,970 million compared to Rs 33,538 million in Q3FY24, with Gross margin of 69.4%. Employee Benefits cost was 17.5% of sales at Rs 9,844 million compared to Rs 8,892 million in Q3FY24. Manufacturing and other expenses were at 30.2% of sales at Rs 16,959 million compared to Rs 15,601 million in Q3FY24. PBT at Rs 10,713 million at 19.1%, up 45.5% YoY from Rs 7,361 million in Q3FY24. Investment in R&D; for the quarter was Rs 4,344 million (7.7 % of sales). Nilesh Gupta, Managing Director, Lupin, said: “Our third-quarter results highlight our continued strength, with both revenue and EBITDA showing sustained growth. US revenues led by building scale in new products have been pivotal for our growth, supported by a strong nine-month performance from our India and EMEA regions. We look forward to maintaining this momentum in the ensuing quarters backed by growth in sales, commercial and operating efficiencies, and strong compliance.” Result PDF